Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00707317
Registration number
NCT00707317
Ethics application status
Date submitted
25/06/2008
Date registered
30/06/2008
Date last updated
16/12/2015
Titles & IDs
Public title
T Cell Interferon-gamma Release Assay (TIGRA) in Immunocompromised Individuals
Query!
Scientific title
Prospective Head-to-head Comparison of the Two Commercially Available Approved TIGRA (QuantiFERON-TB Gold In-Tube and T.SPOT.TB) With the Established Mendel-Mantoux Skin-test in Immunocompromized Patients
Query!
Secondary ID [1]
0
0
TBNET-TIGRA
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
TBNET-TIPS
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Tuberculosis
0
0
Query!
Monitoring, Immunologic
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Infection
0
0
0
0
Query!
Studies of infection and infectious agents
Query!
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
1 - HIV infected individuals
2 - patients with chronic renal failure
3 - patients after solid organ transplantation (lung, liver, kidney, kidney-pancreas)
4 - patients with rheumatoid arthritis
5 - stem cell transplant recipients
6 - immunocompromised patients with confirmed tuberculosis
7 - immunocompetent controls with no known risk of exposure or tuberculosis
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
IGRA performance
Query!
Assessment method [1]
0
0
performance of two IGRAs and skin test in immunocompromised patients
Query!
Timepoint [1]
0
0
at the time of analysis
Query!
Secondary outcome [1]
0
0
active tuberculosis on follow-up
Query!
Assessment method [1]
0
0
Active TB on follow-up depending on test result
Query!
Timepoint [1]
0
0
variable follow-up on all patients
Query!
Eligibility
Key inclusion criteria
- Individual as specified for the study population
- Written informed consent
- Indication to perform tuberculin skin test(suspect latent infection, according to
standard guidelines, differential diagnosis)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
- <18 years of age
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/06/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/05/2011
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1843
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Cellestis Limited - Carnegie
Query!
Recruitment postcode(s) [1]
0
0
- Carnegie
Query!
Recruitment outside Australia
Country [1]
0
0
Bulgaria
Query!
State/province [1]
0
0
Sofia
Query!
Country [2]
0
0
Denmark
Query!
State/province [2]
0
0
Herlev
Query!
Country [3]
0
0
Germany
Query!
State/province [3]
0
0
Borstel
Query!
Country [4]
0
0
Germany
Query!
State/province [4]
0
0
Frankfurt
Query!
Country [5]
0
0
Germany
Query!
State/province [5]
0
0
Freiburg
Query!
Country [6]
0
0
Germany
Query!
State/province [6]
0
0
Homburg
Query!
Country [7]
0
0
Greece
Query!
State/province [7]
0
0
Mezourlo-Larissa
Query!
Country [8]
0
0
Italy
Query!
State/province [8]
0
0
Milan
Query!
Country [9]
0
0
Italy
Query!
State/province [9]
0
0
Roma
Query!
Country [10]
0
0
Italy
Query!
State/province [10]
0
0
Tradate
Query!
Country [11]
0
0
Netherlands
Query!
State/province [11]
0
0
The Hague
Query!
Country [12]
0
0
Portugal
Query!
State/province [12]
0
0
Lisbon
Query!
Country [13]
0
0
Romania
Query!
State/province [13]
0
0
Bucharest
Query!
Country [14]
0
0
Spain
Query!
State/province [14]
0
0
Barcelona
Query!
Country [15]
0
0
Sweden
Query!
State/province [15]
0
0
Stockholm
Query!
Country [16]
0
0
Switzerland
Query!
State/province [16]
0
0
Geneva
Query!
Country [17]
0
0
Turkey
Query!
State/province [17]
0
0
Ankara
Query!
Country [18]
0
0
United Kingdom
Query!
State/province [18]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Tuberculosis Network European Trialsgroup
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Until recently, the tuberculin skin test (TST) was the only available diagnostic assay for
detection of latent infection with M. tuberculosis (LTBI). Despite the low overall incidence
of symptomatic tuberculosis infection in low-prevalence countries, the potential mortality
and morbidity mandate constant vigilance to identify patients at risk for reactivation. Due
to systemic immunosuppression, immunocompromised patients with latent M. tuberculosis
infection are at increased risk of progression to active disease. This applies to patients
with various causes of immunodeficiency such as HIV-infected patients, allogeneic stem cell
and solid organ transplant recipients, patients with rheumatoid arthritis and patients with
chronic renal failure. Therefore, current guidelines aimed at preventing tuberculosis
infection in immunocompromized individuals recommend a generalized screening for evidence of
latent infection to target appropriate preventative prophylaxis. At present, tuberculosis
control programs exclusively rely on the tuberculin skin test to identify a latent infection
in asymptomatic individuals.
Recently, novel in vitro assays termed T cell interferon-gamma release assay (TIGRA) have
become available that are based on the detection of interferon-gamma (IFN-gamma) production
in T cells or supernatants after stimulation with highly specific antigens of M.
tuberculosis. Two TIGRA are commercially available, the ELISPOT based T.SPOT.TB and the ELISA
based QuantiFERON-TB Gold test (now available as an "IN-TUBE" version).
The aim of the study is a prospective comparison of the two commercially available approved
TIGRA (QuantiFERON-TB Gold In-Tube and T.SPOT.TB) with the established Mendel-Mantoux
skin-test in immunocompromized patients (main focus on sensitivity and specificity).
The study hypotheses are as follows:
1. In immunocompromised patients, the two commercially available approved TIGRA
(QuantiFERON-TB Gold In-Tube and T.SPOT.TB) have increased sensitivity and specificity
as compared to the established Mendel-Mantoux skin-test.
2. Results from QuantiFERON-TB Gold In-Tube and T.SPOT.TB do not differ in
immunocompromised patients.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00707317
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Martina Sester, PhD
Query!
Address
0
0
Department of Transplant and Infection Immunology, University of the Saarland, 66421 Homburg
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00707317
Download to PDF